Sunday, 15 April 2018 10:49

Anticoagulation news items. Week commencing 2nd April and 9th April 2018

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial

European Heart Journal

In this randomised comparison involving 1500 patients it was shown that rates of strokes, systemic emboli, deaths, and bleeds were low for both apixaban and heparin/vitamin K antagonist (eg warfarin) treated AF patients undergoing cardioversion.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: